Trial Profile
A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms EMPA-KIDNEY
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International
- 05 Mar 2024 Planned End Date changed from 31 Jan 2025 to 5 Jul 2024.
- 01 Feb 2024 Results (n=660) assessing effects of sodium glucose co-transporter 2 inhibition on bioimpedance-derived "Fluid Overload" and adiposity in a CKD population, published in the Journal of the American Society of Nephrology.
- 23 Jan 2024 According to an Boehringer Ingelheim (Canada) Ltd. media release, Boehringer Ingelheim (Canada) Ltd. and Eli Lilly Canada Inc. announced today Health Canada has authorized Jardiance (empagliflozin) to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular and renal death in adults with chronic kidney disease and authorization by Health Canada is supported by the results from EMPA-KIDNEY.